NLRP3 and melanoma: The combination of NLRP3 inhibition and anti-PD-1 antibody has obtained a synergized effect via the suppression of the function of MDSCs.379 In parallel with this, the activation of NLRP3 is also responsible for the role of tumorous PD-L1 in the resistance to anti-PD-1 immunotherapy through the regulation of MDSCs.380 In aggregate, inflammasomes play an oncogenic role in melanoma via the simultaneous effect on both tumor cell behavior and antitumor immunity.